Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Cytosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL10767383 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRF2KLK1KLK5 | |
| Cytosine SCHEMBL28199181 | 0.93 | DYRK1A (0.34) | DYRK1ATSHRF2KLK1KLK5 | |
| Cytosine SCHEMBL27595867 | 0.90 | TSHR (0.40) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL4657334 | 0.89 | DYRK1A (0.44) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL1330400 | 0.89 | — | — | |
| Cytosine SCHEMBL1330710 | 0.89 | — | — | |
| Cytosine SCHEMBL4059 | 0.89 | — | — | |
| Cytosine SCHEMBL8910522 | 0.88 | TSHR (0.43) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL176467 | 0.88 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1JAK2 | |
| Cytosine SCHEMBL10623341 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101001646-B | Stabilized synthetic immunogen delivery system | UNITED BIOMEDICAL INC | 2014-01-01 | — | — | CN | claimed |
| EP-1931390-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE | BAYHILL THERAPEUTICS INC (US) | 2012-07-25 | — | — | EP | claimed |
| EP-1572074-B1 | STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM | UNITED BIOMEDICAL INC (US) | 2012-01-11 | — | — | EP | claimed |
| US-8088388-B2 | Complexing; water in oil emulsion; immunostimulant | UNITED BIOMEDICAL, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-8084015-B2 | Immunostimulatory complex of a cationic peptide immunogen and anionic CpG single-stranded DNA oligonucleotide | UNITED BIOMEDICAL, INC. (US) | 2011-12-27 | — | — | US | claimed |
| EP-1572074-A4 | STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM | UNITED BIOMEDICAL INC (US) | 2008-04-30 | — | — | EP | claimed |
| EP-1572074-A2 | STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM | United Biomedical, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040009897-A1 | Stabilized synthetic immunogen delivery system | VAXXINITY, INC. | 2004-01-15 | — | — | US | claimed |
| US-20030165478-A1 | Stabilized synthetic immunogen delivery system | VAXXINITY, INC. | 2003-09-04 | — | — | US | claimed |
| WO-2003068169-A2 | STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM | UNITED BIOMEDICAL INC. (US) | 2003-08-21 | — | — | WO | claimed |
| EP-1315803-A2 | ENZYMES HAVING HIGH TEMPERATURE POLYMERASE ACTIVITY AND METHODS OF USE THEREOF | DIVERSA CORPORATION (US) | 2003-06-04 | — | — | EP | claimed |
| US-20020132243-A1 | Enzymes having high temperature polymerase activity and methods of use thereof | VERENIUM CORPORATION | 2002-09-19 | — | — | US | claimed |
| WO-2002020735-A2 | ENZYMES HAVING HIGH TEMPERATURE POLYMERASE ACTIVITY AND METHODS OF USE THEREOF | DIVERSA CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20230346821-A1 | RNA AND NUCLEIC ACID CARRIER INCLUDING THE SAME | LEMONEX INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2023187639-A1 | FUNCTIONAL NUCLEIC ACID MOLECULES FOR EPIGENETIC REGULATION | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-11701378-B2 | RNA and nucleic acid carrier including the same | LEMONEX INC. (KR) | 2023-07-18 | — | — | US | disclosed |
| WO-1998054363-A1 | APPLICATION OF HELIX-RANDOM CHAIN THERMODYNAMICS TO NUCLEIC ACID ANALYSIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0864002-A1 | METHODS AND COMPOSITIONS FOR DETECTION OF SPECIFIC NUCLEOTIDE SEQUENCES | Ramberg, Elliot R. (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5658728-A | CONSISTS OF FLAT SUBSTRATE AND THREE-DIMENSIONAL PATTERN FORMED ON IT BY POSITIONING INDIVISUL ATOMS OR MOLECULES SELECTED FROM HALOGEN, OXYGEN OR NITROGEN TO FORM HILLOCKS, CAPABLE OF BINIDNG TO COMPLEMENTARY PORTION OF DNA OR RNA | GOSNEY JR WILLIAM MILTON (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997015691-A1 | METHODS AND COMPOSITIONS FOR DETECTION OF SPECIFIC NUCLEOTIDE SEQUENCES | RAMBERG ELLIOT R (US) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030165478-A1 | Stabilized synthetic immunogen delivery system | IFNG, IL36G, LY96 | DYRK1A 2263/4885TSHR 2438/4885F2 642/4885 |
| US-20040009897-A1 | Stabilized synthetic immunogen delivery system | TLR9, MYD88, IFNG | DYRK1A 1727/4885TSHR 1663/4885F2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.